Sjögren's syndrome: Current concepts

Advances in Internal Medicine

Volumn 47, Issue , 2001, Pages 191-217

  Manoussakis, Menelaos N ^a   Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; B LYMPHOCYTE; BIOLOGICAL MODEL; DISEASE COURSE; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; REVIEW; SJOEGREN SYNDROME;

ADULT; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MODELS, IMMUNOLOGICAL; SJOGREN'S SYNDROME;

EID: 0035749336     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Moutsopoulos HM, Chused TM, Mann DL, et al: Sjögren's syndrome (sicca syndrome): Current issues. Ann Intern Med 92:212-226, 1980.
2. Manoussakis MN, Talal N, Moutsopoulos HM: Sjögren's syndrome, in Rose NR, Mackay IR (eds): The Autoimmune Diseases, ed 3. San Diego, Calif, Academic Press, 1998, pp 381-404.
3. Jacobsson LTH, Axell TE, Hansen BU, et al: Dry eyes or mouth. An epidemiological study in Swedish adults with special reference to primary Sjögren's syndrome. / Autoimmun 2:521-527, 1989.
4. Dafni UG, Tzioufas AG, Staikos P, et al: Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis 56:521-525, 1997.
5. Stiller M, Golder W, Doring E: Primary and secondary Sjögren's syndrome in children: A comparative study. Clin Oral Investig 4:176182, 2000.
6. Isidor F, Brondum K, Hansen HJ, et al: Outcome of treatment with implant-retained dental prostheses in patients with Sjögren's syndrome. Int J Oral Maxillofac Implants 14:736-743, 1999.
7. Castro-Poltronieri A, Alarcon-Segovia D: Articular manifestation of primary Sjögren's syndrome. / Kheumatol 10:485-490, 1983.
8. Giles I, Isenberg D: Fatigue in primary Sjögren's syndrome: Is there a link with the fibromyalgia syndrome? Ann Rheum Dis 59:875-878, 2000.
9. Papiris SA, Maniati M, Constantopoulos SH, et al: Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 58:61-64, 1999.
10. Tsianos EV, Hoomagle JH, Fox PC, et al: Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology 11:730-734, 1990.
11. Iltanen S, Collin P, Korpela M, et al: Celiac disease and markers of celiac disease latency in patients with primary Sjögren's syndrome. Am J Gastroenterol 94:1042-1046, 1999.
12. Kassan SS, Talal N: Renal disease with Sjögren's syndrome, in Talal N, Moutsopoulos HM, Kassan SS (eds): Sjögren's Syndrome. Clinical and Immunological Aspects. Berlin, Springer-Verlag, 1987, pp 96-101.
13. Goules A, Masouridi S, Tzioufas AG, et al: Clinically significant and biopsy-documented renal involvement in primary Sjögren's syndrome. Medicine (Baltimore) 79:241-249, 2000.
14. Tektonidou M, Kaskani E, Skopouli FN, et al: Microvascular abnormalities in Sjögren's syndrome: Nailfold capillaroscopy. Rheumatology (Oxford) 38:826-830, 1999.
15. Tsokos M, Lazarou SA, Moutsopoulos HM: Vasculitis in primary Sjögren's syndrome: Histologie classification and clinical presentation. Am J Clin Pathol 88:26-31, 1987.
16. Skopouli FN, Dafni U, loannidis JP, et al: Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 29:296-304, 2000.
17. Malinow KL, Molina R, Gordon B, et al: Neuropsychiatrie dysfunction in primary Sjögren's syndrome. Ann Intern Med 103:344-349, 1985.
18. Andonopoulos AP, Christodoulou J, Ballas C, et al: Autonomie cardiovascular neuropathy in Sjögren's syndrome. A controlled study. / Rheumatol 25:2385-2388, 1998.
19. Waterman SA, Gordon TP, Rischmueller M: Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 43:1647-1654, 2000.
20. Bacman SR, Berra A, Sterin-Borda L, et al: Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res 17:1135-1142, 1998.
21. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, et al: Hypofunction of the stress axis in Sjogren's syndrome. / Rheumatol 25:15081514, 1998.
22. Skopouli FN, Papanikolaou S, Malamou-Mitsi, et al: Obstetric and gynaecological profile in patients with primary Sjogren's syndrome. Ann Rheum Dis 53:569-573, 1994.
23. Bunim JJ, Talal N: The association of malignant lymphoma with Sjogren's syndrome. Trans Assoc Am Physicians 76:45-56, 1963.
24. Kassan SS, Thomas T, Moutsopoulos HM, et al: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888-892, 1978.
25. Fox RI, Koh K, Saito I: Lymphoproliferative disorders in Sjogren's syndrome, in Homma M, Sugai S, Tojo T, et al (eds): Sjogren's Syndrome. State of the Art. Amsterdam, Kugler, 1994, pp 199-203.
26. Voulgarelis M, Dafni UG, Isenberg DA, et al: Malignant lymphoma in primary Sjogren's syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42:1765-1772, 1999.
27. Tzioufas AG, Boumba DS, Skopouli FN, et al: Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predicting factors for development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 39:767-772, 1996.
28. Moutsopoulos HM, Manoussakis MN: Lumping or splitting autoimmune rheumatic disorders? Lessons from Sjogren's syndrome. Br J Rheumatol 37:1263-1264, 1998.
29. Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al: Differences in the clinical presentation of sicca syndrome in the presence and in the absence of rheumatoid arthritis. Am J Med 66:733-736, 1979.
30. Andonopoulos AP, Skopouli FN, Dimou GS, et al: Sjogren's syndrome in systemic lupus erythematosus. / Rheumatol 17:201-204, 1990.
31. Medsger TA Jr: Sjogren's syndrome and systemic sclerosis (scleroderma), in Talal N, Moutsopoulos HM, Kassan SS (eds): Sjogren's Syndrome. Clinical and Immunological Aspects. Berlin, SpringerVerlag, 1987, pp 182-187.
32. Drosos AA, Pennée YL, Elisaf M, et al: Sjogren's syndrome in patients with the CREST variant of progressive systemic scleroderma. / Rheumatol 18:1685-1688, 1991.
33. Vlachoyiannopoulos PG, Drosos AA, Wiik A, et al: Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297-301, 1993.
34. Gannot G, Lancaster HE, Fox PC: Clinical course of primary Sjogren's syndrome: Salivary, oral, and sérologie aspects. J Rheumatol 27:19051909, 2000.
35. Martens PB, Pillemer SR, Jacobsson LT, et al: Survivorship in a population based cohort of patients with Sjogren's syndrome, 19761992. J Rheumatol 26:1296-1300, 1999.
36. Kong L, Ogawa N, Nakabayashi T, et al: Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 40:87-97, 1997.
37. Matsumura R, Umemiya K, Kagami M, et al: Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjogren's syndrome. Clin Exp Rheumatol 16:561-568, 1998.
38. Polihronis M, Tapinos NI, Theocharis SE, et al: Modes of epithelial cell death and repair in Sjogren's syndrome. Clin Exp Immunol 114:485490, 1998.
39. Moutsopoulos HM: Sjogren's syndrome: Autoimmune epithelitis. Clin Immunol Immunopathol 72:162-165, 1994.
40. Fox RI, Kang HI, Ando D, et al: Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 152:5532-5539,1994.
41. Skopouli FN, Moutsopoulos HM: Cytokines in Sjogren's syndrome, in Brennan FM, Feldmann M (eds): Cytokines in Autoimmunity. Austin, Tex, RG Landes, 1996, pp 121-136.
42. Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, et al: Induction of salivary gland epithelial cell injury in Sjogren's syndrome: In vitro assessment of T cell-derived cytokines and Fas protein expression. / Autoimmunity 17:141-153, 2001.
43. Azuma M, Aota K, Tamatani T, et al: Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjogren's syndrome salivary glands. Arthritis Rheum 43:1756-1767, 2000.
44. Xanthou G, Tapinos NI, Polihronis M, et al: CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogren's syndrome. Clin Exp Immunol 118:154-163, 1999.
45. Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, et al: Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum 42:229-239, 1999.
46. Kapsogeorgou EK, Dimitriou ID, Abu Helu RF, et al: Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjogren's syndrome: High expression of intercellular adhesion molecule-1 (ICAM.l) in biopsy specimens and cultured cells. Clin Exp Immunol 124:126-133, 2001.
47. Konttinen YT, Platts LAM, Tuominen S, et al: Role of nitric oxide in Sjogren's syndrome. Arthritis Rheum 40:875-883, 1997.
48. Konttinen YT, Halinen S, Hanemaaijer R, et al: Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinasQ implicated in the pathogenesis of Sjogren's syndrome. Matrix Biol 17:335-347, 1998.
49. Lindahl G, Hedfors E, Klareskog L, et al: Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjogren's syndrome. Clin Exp Immunol 61:475-482, 1985.
50. Xanthou G, Polihronis M, Tzioufas AG, et al: Lymphoid chemokine messsenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients. Arthritis Rheum 44:408-418, 2001.
51. Tzioufas AG, Hantoumi I, Polihronis M, et al: Autoantibodies to La/SSB in patients with primary Sjögren's syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs). J Autoimmun 13:429-434, 1999.
52. Skopouli FN, Kousvelari E, Mertz P, et al: C-myc mRNA expression in minor salivary glands of patients with Sjögren's syndrome. JRheumatol 19:693-699, 1992.
53. Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN: Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J Immunol 166:3107-3113, 2001.
54. Harley JB: Autoantibodies in Sjögren's syndrome, in Talal N, Moutsopoulos HM, Kassan SS (eds): Sjögren's Syndrome. Clinical and Immunological Aspects. Berlin, Springer-Verlag, 1987, pp 218-234.
55. Vitali C, Bombardieri S, Moutsopoulos HM, et al: Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: Results of a prospective multicentre study. Ann Rheum Dis 55:116-121, 1996.
56. Manoussakis MN, Tzioufas AG, Pange PJE, et al: Serological profiles in subgroups of patients with Sjögren's syndrome. Scand J Rheumatol 61:89S-92S, 1986.
57. Haneji N, Nakamura T, Takio K, et al: Identification of a-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science 276: 604, 1997.
58. Schmid U, Helbron D, Lennert K: Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome). Virchows Arch 395:11-41, 1982.
59. Tapinos NI, Polihronis M, Moutsopoulos HM: Lymphoma in Sjögren's syndrome. Novel p53 mutations. Arthritis Rheum 42:1466-1472,1999.
60. Mann D: Immunogenetics of Sjögren's syndrome, in Talal N, Moutsopoulos HM, Kassan SS (eds): Sjögren's Syndrome. Clinical and Immunological Aspects. Berlin, Springer-Verlag, 1987, pp 235-243.
61. Harley JB, Reichlin M, Arnett FC, et al: Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome. Science 232:1145-1147, 1986.
62. Roitberg-Tambur A, Friedmann A, Safirmann C, et al: Molecular analysis of HLA class II genes in primary Sjögren's syndrome: A study of Israeli and Greek non-Jewish patients. Hum Immunol 36:235-242, 1993.
63. Fox RI, Koh K, Saito I: Viral factors in the etiology of Sjögren's syndrome, in Homma M, Sugai S, Tojo T, et al (eds): Sjögren's Syndrome. State of the Art. Amsterdam, Kugler, 1994, pp 163-169.
64. Haddad J, Deny P, Munz-Gothiel C, et al: Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis-C virus liver disease. Lancet 339:321-323, 1992.
65. Itescu S: Diffuse infiltrative lymphocytosis syndrome in human immunodeficiency virus infection: A Sjögren's-like disease. Rheum Dis Clin North Am 17:99-115, 1991.
66. Drosos AA, Antonopoulos AP, Costopoulos JS, et al: Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol 27:123-127, 1988.
67. Vitali C, Bombardier! S, Jonsson R, et al: Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group, submitted for publication.
68. Chisholm DM, Mason DK: Labial salivary gland biopsy in Sjögren's syndrome. / Clin Pathol 21:656-660, 1968.
69. Vlachoyiannopoulos PG, Moutsopoulos HM: Therapy in Sjögren's syndrome, in Van de Putte LBA, Fürst DE, Williams HJ, et al (eds): Therapy of Systemic Rheumatic Disorders. New York, Marcel Dekker, 1997, pp 615-628.
70. Linardaki G, Moutsopoulos HM: The uncertain role of immunosuppressive agents in Sjögren's syndrome. Cleve Clin J Med 64:523-526, 1997.
71. Ferraccioli GF, Salaffi F, De Vita S, et al: Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OHchloroquine. Clin Exp Rheumatol 14:367-371, 1996.
72. Shiozawa S, Tanaka Y, Shiozawa K: Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. /Interferon Cytokine Res 18:255-262, 1998.
73. Ship JA, Fox PC, Michalek JE, et al: Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: A phase II clinical trial. IFN Protocol Study Group. / Interferon Cytokine Res 19:943-951, 1999.
74. Fox PC, Atkinson JC, Macynski AA, et al: Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151:1149, 1991.
75. Iga Y, Arisawa H, Ogane N, et al: (+/-)-cis-2-methylspiro[l,3oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors. Jpn J Pharmacol 78:373-380, 1998.
76. Fox RI, Chan E, Bentol L, et al: Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 85:62S-67S, 1988.